CN111315748B - 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体 - Google Patents

3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体 Download PDF

Info

Publication number
CN111315748B
CN111315748B CN201880066706.4A CN201880066706A CN111315748B CN 111315748 B CN111315748 B CN 111315748B CN 201880066706 A CN201880066706 A CN 201880066706A CN 111315748 B CN111315748 B CN 111315748B
Authority
CN
China
Prior art keywords
solid form
ing
cancer
solid
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880066706.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111315748A (zh
Inventor
张亚民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinesitherapy Co
Original Assignee
Kinesitherapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinesitherapy Co filed Critical Kinesitherapy Co
Publication of CN111315748A publication Critical patent/CN111315748A/zh
Application granted granted Critical
Publication of CN111315748B publication Critical patent/CN111315748B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201880066706.4A 2017-10-16 2018-10-16 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体 Active CN111315748B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572603P 2017-10-16 2017-10-16
US62/572,603 2017-10-16
PCT/US2018/056083 WO2019079299A1 (en) 2017-10-16 2018-10-16 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (2)

Publication Number Publication Date
CN111315748A CN111315748A (zh) 2020-06-19
CN111315748B true CN111315748B (zh) 2023-06-27

Family

ID=64110166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880066706.4A Active CN111315748B (zh) 2017-10-16 2018-10-16 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体

Country Status (16)

Country Link
US (3) US11407759B2 (enExample)
EP (2) EP4740944A3 (enExample)
JP (2) JP7776258B2 (enExample)
KR (1) KR102891811B1 (enExample)
CN (1) CN111315748B (enExample)
AU (1) AU2018352384B2 (enExample)
CA (1) CA3074037A1 (enExample)
DK (1) DK3697794T3 (enExample)
ES (1) ES3064009T3 (enExample)
FI (1) FI3697794T3 (enExample)
IL (1) IL273920B2 (enExample)
MX (1) MX2020003431A (enExample)
PL (1) PL3697794T3 (enExample)
PT (1) PT3697794T (enExample)
WO (1) WO2019079299A1 (enExample)
ZA (1) ZA202002740B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250070131A (ko) 2017-08-11 2025-05-20 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Crystalline Polymorphism of Organic Compounds;CAIRA ED-MONTCHAMP JEAN-LUC;《TOPICS IN CURRENT CHEMISTRY》;19980101;第163-208页 *
From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3 Inhibitors That Suppress Proliferation and Survival of Pancreatic Cancer Cells;Irina N. Gaisina等;《J. Med. Chem.》;20090316;第1853-1863页，表1化合物26，Scheme 1，第1854页左栏第2段-1855页，第1860页左栏第4段 *

Also Published As

Publication number Publication date
JP2024001040A (ja) 2024-01-09
ES3064009T3 (en) 2026-04-22
ZA202002740B (en) 2025-12-17
KR20200100615A (ko) 2020-08-26
AU2018352384B2 (en) 2023-12-21
AU2018352384A1 (en) 2020-05-21
US20200239489A1 (en) 2020-07-30
PT3697794T (pt) 2026-03-04
JP2020536944A (ja) 2020-12-17
IL273920B2 (en) 2025-07-01
JP7776258B2 (ja) 2025-11-26
WO2019079299A1 (en) 2019-04-25
CN111315748A (zh) 2020-06-19
IL273920B1 (en) 2025-03-01
FI3697794T3 (fi) 2026-02-10
CA3074037A1 (en) 2019-04-25
DK3697794T3 (da) 2026-02-02
MX2020003431A (es) 2020-07-29
US11407759B2 (en) 2022-08-09
EP3697794A1 (en) 2020-08-26
BR112020007538A2 (pt) 2020-09-24
US20250115615A1 (en) 2025-04-10
US20220348591A1 (en) 2022-11-03
EP4740944A2 (en) 2026-05-13
IL273920A (en) 2020-05-31
EP4740944A3 (en) 2026-07-29
US12116374B2 (en) 2024-10-15
EP3697794B1 (en) 2025-12-24
PL3697794T3 (pl) 2026-04-07
KR102891811B1 (ko) 2025-11-28

Similar Documents

Publication Publication Date Title
JP7778750B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
US20250115615A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
HK40106022A (en) Solid forms of 9-ing-41
BR112020007538B1 (pt) Forma sólida, processo para preparar a forma sólida, composição farmacêutica, processo para preparar a composição farmacêutica e uso da forma sólida
BR122025019554A2 (pt) Forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5- f]indol-7-il)pirrol-2,5-diona, seus usos, composição farmacêutica e processo para preparar a mesma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant